TARS:NSD-Tarsus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 47.57

Change

-1.51 (-3.08)%

Market Cap

USD 1.80B

Volume

0.62M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.61 (+0.94%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

-16.67 (-2.03%)

USD 92.70B
ARGX argenx NV ADR

+5.40 (+0.91%)

USD 35.81B
ALNY Alnylam Pharmaceuticals Inc

-4.35 (-1.62%)

USD 34.69B
BGNE BeiGene Ltd

+1.81 (+0.93%)

USD 22.85B
MRNA Moderna Inc

-1.33 (-3.06%)

USD 21.00B
UTHR United Therapeutics Corporatio..

-0.42 (-0.10%)

USD 16.70B
RPRX Royalty Pharma Plc

-0.15 (-0.58%)

USD 16.11B
INCY Incyte Corporation

-0.10 (-0.12%)

USD 14.67B
SMMT Summit Therapeutics PLC

-1.29 (-6.21%)

USD 13.75B

ETFs Containing TARS

FXZ First Trust Materials Alp.. 4.91 % 0.64 %

-0.43 (-1.57%)

N/A
SLX VanEck Steel ETF 4.91 % 0.56 %

-1.13 (-1.57%)

N/A
XME SPDR® S&P Metals and Min.. 4.55 % 0.35 %

-1.05 (-1.57%)

N/A
SMLL Harbor ETF Trust 3.43 % 0.28 %

-0.21 (-1.57%)

N/A
PYZ Invesco DWA Basic Materia.. 3.31 % 0.60 %

-0.87 (-1.57%)

USD 0.06B
PICK 1.56 % 0.39 %

N/A

N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 1.07 % 0.15 %

-0.64 (-1.57%)

N/A
FTA First Trust Large Cap Val.. 0.92 % 0.61 %

+0.17 (+-1.57%)

USD 1.21B
IWC iShares Micro-Cap ETF 0.40 % 0.60 %

-2.49 (-1.57%)

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

-0.11 (-1.57%)

N/A
SMLF iShares MSCI USA Small-Ca.. 0.00 % 0.30 %

-0.44 (-1.57%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 134.91% 93% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 134.91% 93% A 96% N/A
Trailing 12 Months  
Capital Gain 165.46% 89% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 165.46% 89% A- 95% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 11.11% 59% D- 64% D
Dividend Return 11.11% 59% D- 61% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 57.63% 59% D- 34% F
Risk Adjusted Return 19.28% 76% C+ 53% F
Market Capitalization 1.80B 86% B+ 78% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector